Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study

Ophthalmology

Volumn 111, Issue 9, 2004, Pages 1725-1733

  Rosenfeld, Philip J ^a   Saperstein, David A ^b   Bressler, Neil M ^c   Reaves, Troy A ^d   Sickenberg, Michel ^e   Rosa Jr , Robert H ^a   Sternberg Jr , Paul ^b   Aaberg Sr , Thomas M ^b   Aaberg Jr , Thomas M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMORY EYE CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e HÔPITAL OPHTALMIQUE JULES GONIN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PORPHYRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; EVALUATION; EYE INJURY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MEASUREMENT; MULTICENTER STUDY; OCULAR HISTOPLASMOSIS; OPHTHALMOSCOPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; TECHNIQUE; TIME SERIES ANALYSIS; TREATMENT OUTCOME; VISION; VISUAL ACUITY; AGED; CASE REPORT; FEMALE; FUNGAL EYE INFECTION; HISTOPLASMOSIS; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; SAFETY; SUBRETINAL NEOVASCULARIZATION; SYNDROME;

ADULT; AGED; CHOROIDAL NEOVASCULARIZATION; EYE INFECTIONS, FUNGAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HISTOPLASMOSIS; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; SAFETY; SYNDROME; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 4444295827     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2004.02.014     Document Type: Article

References (15)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol. 117:1999;1329-1345
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol. 131:2001;541-560
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol. 119:2001;198-207
4. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin 1-year results of a randomized clinical trial - VIP Report 1. Ophthalmology. 108:2001;841-852
5. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia 2-year results of a randomized clinical trial - VIP Report 3. Ophthalmology. 110:2003;667-673
6. Macular Photocoagulation Study Group, Saperstein D.A., Rosenfeld P.J., Bressler N.M., et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome one-year results of an uncontrolled, prospective case series. Ophthalmology. 109:2002;1499-1505
7. Lewis M.L., Van Newkirk M.R., Gass J.D.M. Follow-up study of presumed ocular histoplasmosis syndrome. Ophthalmology. 87:1980;390-399
8. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Arch Ophthalmol. 105:1987;1499-1507
9. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 109:1991;1109-1114
10. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol. 112:1994;500-509
11. Verteporfin Roundtable 2000 and 2001 Participants. Laser photocoagulation for neovascular lesions nasal to the fovea. Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes. Arch Ophthalmol. 113:1995;56-61
12. Kleiner R.C., Ratner C.M., Enger C., Fine S.L. Subfoveal neovascularization in the ocular histoplasmosis syndrome. A natural history study. Retina. 8:1988;225-229
13. Olk R.J., Burgess D.B., McCormick P.A. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis. Ophthalmology. 91:1984;1592-1602
14. Fine S.L., Wood W.J., Isernhagen R.D., et al. Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome results of a pilot randomized clinical trial. [letter] Arch Ophthalmol. 111:1993;19-20
15. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 22:2002;6-18